• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk factors associated with bloodstream infections among critically ill patients with COVID-19.

作者信息

McMillan Tim, Jones Conor, O'Connor Cavan J, Nolan Daniel, Chan Xin Hui S, Ellis Jayne, Thakker Clare, Kranzer Katharina, Stone Neil Rh, Singer Mervyn, Wilson A Peter R, Arulkumaran Nishkantha

机构信息

Division of Medicine, Bloomsbury Institute for Intensive Care Medicine, University College London, Cruciform Building, Gower St, London WC1E 6BT, United Kingdom.

Department of Clinical Microbiology, University College London NHS Foundation Trust, London, United Kingdom.

出版信息

J Infect. 2021 Nov;83(5):e1-e3. doi: 10.1016/j.jinf.2021.09.010. Epub 2021 Sep 16.

DOI:10.1016/j.jinf.2021.09.010
PMID:34537320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8444445/
Abstract
摘要

相似文献

1
Risk factors associated with bloodstream infections among critically ill patients with COVID-19.新型冠状病毒肺炎（COVID-19）危重症患者血流感染的相关危险因素。
J Infect. 2021 Nov;83(5):e1-e3. doi: 10.1016/j.jinf.2021.09.010. Epub 2021 Sep 16.
2
Venous thromboembolism is not a risk factor for the development of bloodstream infections in critically ill COVID-19 patients.静脉血栓栓塞并非危重症COVID-19患者发生血流感染的危险因素。
Thromb Res. 2021 Oct;206:128-130. doi: 10.1016/j.thromres.2021.08.019. Epub 2021 Aug 25.
3
Secondary bloodstream infection in critically ill patients with COVID-19.COVID-19 重症患者的继发性血流感染。
J Int Med Res. 2021 Dec;49(12):3000605211062783. doi: 10.1177/03000605211062783.
4
Best practice statements and recommendations for caring for critically ill patients with COVID-19.关于照顾 COVID-19 重症患者的最佳实践声明和建议。
Ann Intern Med. 2020 Jun 16;172(12):JC62. doi: 10.7326/ACPJ202006160-062.
5
COVID-19-Associated Pulmonary Aspergillosis in the Critical Care Setting.COVID-19 相关的重症监护病房肺曲霉病。
AACN Adv Crit Care. 2021 Dec 15;32(4):398-403. doi: 10.4037/aacnacc2021226.
6
The Gut Microbiota of Critically Ill Patients With COVID-19.COVID-19 危重症患者的肠道微生物群。
Front Cell Infect Microbiol. 2021 Jun 29;11:670424. doi: 10.3389/fcimb.2021.670424. eCollection 2021.
7
Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients.糖尿病是危重症患者下呼吸道样本中 SARS-CoV-2 病毒持续脱落的一个风险因素。
Endocrine. 2020 Dec;70(3):454-460. doi: 10.1007/s12020-020-02465-4. Epub 2020 Sep 1.
8
COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.COVID-19 增加了 ICU 获得性血流感染的风险：来自多中心 OUTCOMEREA 网络的病例队列研究。
Intensive Care Med. 2021 Feb;47(2):180-187. doi: 10.1007/s00134-021-06346-w. Epub 2021 Jan 27.
9
A survey on acute kidney injury in severely and critically ill COVID-19 patients without chronic kidney disease.一项关于无慢性肾脏病的重症 COVID-19 患者急性肾损伤的调查。
Ann Palliat Med. 2021 Jun;10(6):6198-6207. doi: 10.21037/apm-20-2170. Epub 2021 May 17.
10
Steroid use in elderly critically ill COVID-19 patients.老年危重症 COVID-19 患者使用类固醇。
Eur Respir J. 2021 Oct 7;58(4). doi: 10.1183/13993003.00979-2021. Print 2021 Oct.

引用本文的文献

1
Impact of intensified prevention measures on the rate of hospital-acquired bloodstream infections among mechanically ventilated COVID-19 patients.强化预防措施对新型冠状病毒肺炎机械通气患者医院获得性血流感染发生率的影响
Antimicrob Steward Healthc Epidemiol. 2023 Dec 14;3(1):e235. doi: 10.1017/ash.2023.505. eCollection 2023.
2
Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients.地塞米松对危重症 COVID-19 患者病原体谱的影响。
Viruses. 2023 Apr 28;15(5):1076. doi: 10.3390/v15051076.
3
Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.在新冠疫情第一波和第二波期间，减少重症监护病房广谱抗生素的使用并未对死亡率产生不利影响。
J Hosp Infect. 2022 Jun;124:37-46. doi: 10.1016/j.jhin.2022.03.007. Epub 2022 Mar 23.

本文引用的文献

1
Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.地塞米松和托珠单抗治疗显著降低了 C 反应蛋白和降钙素原检测 COVID-19 患者继发细菌性感染的价值。
Crit Care. 2021 Aug 5;25(1):281. doi: 10.1186/s13054-021-03717-z.
2
Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case-control matched multicentre study (BACTCOVID).重症新型冠状病毒肺炎患者医院获得性血流感染的免疫调节治疗、危险因素及结局：一项西班牙病例对照匹配多中心研究（BACTCOVID）
Clin Microbiol Infect. 2021 Nov;27(11):1685-1692. doi: 10.1016/j.cmi.2021.06.041. Epub 2021 Jul 7.
3
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.在国际严重急性呼吸系统与传染病联盟-世界卫生组织合作中心英国队列研究中，对首次大流行浪潮期间因 COVID-19 住院的患者中的合并感染、继发感染和抗菌药物使用情况进行的一项多中心、前瞻性队列研究。
Lancet Microbe. 2021 Aug;2(8):e354-e365. doi: 10.1016/S2666-5247(21)00090-2. Epub 2021 Jun 2.
4
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
5
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.严重的免疫抑制，而非细胞因子风暴，是 COVID-19 感染的特征。
JCI Insight. 2020 Sep 3;5(17):140329. doi: 10.1172/jci.insight.140329.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
Co-infections in people with COVID-19: a systematic review and meta-analysis.COVID-19 患者合并感染：系统评价和荟萃分析。
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
8
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
9
Immunosuppression in patients who die of sepsis and multiple organ failure.死于脓毒症和多器官衰竭的患者的免疫抑制。
JAMA. 2011 Dec 21;306(23):2594-605. doi: 10.1001/jama.2011.1829.